Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the present invention relates to novel arylalkane-sulfonamides of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions.
• the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and especially their use as endothelin receptor antagonists.
• Endothelins are 21 -amino acid peptides produced and active in almost all tissues (Yanagisawa M et al.: Nature (1988) 332:411). Endothelins are potent vasoconstrictors and important mediators of cardiac, renal, endocrine and immune functions (Mc illen MA et al.: J Am Coll Surg (1995) 180:621 ). They participate in bronchoconstriction and regulate neurotransmitter release, activation of inflammatory cells, fibrosis, cell proliferation and cell differentiation (Rubanyi GM et al.: Pharmacol Rev (1994) 46:328).
• ET A receptor Two endothelin receptors have been cloned and characterized in mammals (ETA, ET B ) (Arai H et al.: Nature (1990) 348:730; Sakurai T et al.: Nature (1990) 348:732).
• the ET A receptor is characterized by higher affinity for ET-1 and ET-2 than for ET-3. It is predominant in vascular smooth muscle cells and mediates vasoconstricting and proliferative responses (Ohlstein EH et al.: Drug Dev Res (1993) 29:108).
• the ETB receptor has equivalent affinity for the 3 endothelin isopeptides and binds the linear form of endothelin, tetra-ala- endothelin, and sarafotoxin S6C (Ogawa Y et al.: BBRC (1991) 178:248).
• This receptor is located in the vascular endothelium and smooth muscles, and is also particularly abundant in lung and brain.
• ET A and ET B receptors are highly similar in structure and belong to the superfamily of G-protein coupled receptors.
• ET-1 A pathophysiological role has been suggested for ET-1 in view of its increased plasma and tissue levels in several disease states such as hypertension, sepsis, atherosclerosis, acute myocardial infarction, congestive heart failure, renal failure, migraine and asthma.
• endothelin receptor antagonists have been studied extensively as potential therapeutic agents. Endothelin receptor antagonists have demonstrated preclinical and/or clinical efficacy in various diseases such as cerebral vasospasm following subarachnoid hemorrhage, heart failure, pulmonary and systemic hypertension, neurogenic inflammation, renal failure and myocardial infarction.
• membranes of CHO cells expressing human recombinant ET A or ET B receptors were used. Microsomal membranes from recombinant CHO cells were prepared and the binding assay made as previously described (Breu V., et al, FEBS Lett 1993; 334:210).
• the assay was performed in 200 uL 50 mM Tris/HCI buffer, pH 7.4, including 25 mM MnCI 2 , 1 mM EDTA and 0.5% (w/v) BSA in polypropylene microtiter plates.
• Membranes containing 0.5 ug protein were incubated for 2 h at 20°C with 8 pM [ 125 I]ET-1 (4000 cpm) and increasing concentrations of unlabelled antagonists. Maximum and minimum binding were estimated in samples without and with 100 nM ET-1 , respectively. After 2 h, the membranes were filtered on filterplates containing GF/C filters (Unifilterplates from Canberra Packard S.A. Zurich, Switzerland).
• IC 50 was calculated as the concentration of antagonist inhibiting 50 % of the specific binding of ET-1.
• Example 1 27 6650 Example 2 20 899 Example 5 3 323 Example 7 4 3310 Example 10 9 2410 Example 13 4 3680 Example 14 6 2230 Example 19 3 1930 Example 29 10 406 Example 39 3 261 Example 46 7 2360 Example 47 24 2720 Example 49 4 2490 Example 52 5 1770 Example 61 10 1140 Example 71 115 >10000 Example 81 24 824
• the functional inhibitory potency of the endothelin antagonists was assessed by their inhibition of the contraction induced by endothelin-1 on rat aortic rings (ET A receptors) and of the contraction induced by sarafotoxin S6c on rat tracheal rings (ETB receptors).
• E A receptors endothelin-1 on rat aortic rings
• EB receptors sarafotoxin S6c on rat tracheal rings
• Each ring was suspended in a 10 ml isolated organ bath filled with Krebs- Henseleit solution (in mM; NaCl 115, KCI 4.7, MgSO 4 1.2, KH 2 PO 4 1.5, NaHCO 3 25, CaCI 2 2.5, glucose 10) kept at 37°C and gassed with 95% O 2 and 5% CO 2 .
• the rings were connected to force transducers and isometric tension was recorded (EMKA Technologies SA, Paris, France).
• the rings were stretched to a resting tension of 3 g (aorta) or 2 g (trachea). Cumulative doses of ET-1 (aorta) or sarafotoxin S6c (trachea) were added after a 10 min incubation with the test compound or its vehicle.
• the functional inhibitory potency of the test compound was assessed by calculating the concentration ratio, i.e. the shift to the right of the EC50 induced by different concentrations of test compound.
• EC 50 is the concentration of endothelin needed to get a half-maximal contraction
• pA 2 is the negative logarithm of the antagonist concentration which induces a two-fold shift in the EC 5 0 value.
• the described compounds can be used for treatment of diseases which are associated with an increase in vasoconstriction, proliferation or inflammation due to endothelin.
• diseases which are associated with an increase in vasoconstriction, proliferation or inflammation due to endothelin.
• diseases are hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, portal hypertension and pulmonary hypertension.
• Atherosclerosis prevention of restenosis after balloon or stent angioplasty, inflammation, stomach and duodenal ulcer, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain as well as other diseases presently known to be related to endothelin.
• the compounds can be administered orally, rectally, parenterally, e.g. by intravenous, intramuscular, subcutaneous, intrathecal or transdermal administration or sublingually or as ophthalmic preparation or administered as aerosol.
• parenterally e.g. by intravenous, intramuscular, subcutaneous, intrathecal or transdermal administration or sublingually or as ophthalmic preparation or administered as aerosol.
• applications are capsules, tablets, orally administered suspensions or solutions, suppositories, injections, eye-drops, ointments or aerosols/nebulizers.
• Preferred applications are intravenous, intramuscular, or oral administrations as well as eye drops.
• the dosage used depends upon the type of the specific active ingredient, the age and the requirements of the patient and the kind of application. Generally, dosages of 0.1 - 50 mg / kg body weight per day are considered.
• the preparations with compounds can contain inert or as well pharmacodynamically active excipients. Tablets or granules, for example, could contain a number of binding agents, filling excipients, carrier substances or diluents.
• the present invention relates to arylethene-suifonamides of the general formula
• R 1 and R 2 represent aryl; heteroaryl;
• R 3 represents phenyl; mono-, di- or tri-substituted phenyl substituted with lower alkyl, lower alkenyl, lower alkynyl, phenyl, lower alkoxy, amino, lower alkylamino, amino-lower alkyl, trifluoromethyl, trifluoromethoxy, halogen, lower alkylthio, hydroxy, hydroxy-lower alkyl, cyano, carboxyl, lower alkanoyl, formyl; benzofuranyl; aryl; heteroaryl;
• R 4 represents hydrogen; halogen; trifluoromethyl; lower alkyl; lower alkyl-amino; lower alkoxy; lower alkyl-sulfono; lower alkyl-sulfinyl; lower alkylthio; lower alkylthio-lower alkyl; hydroxy-lower alkyl; lower alkyl-oxy-lower alkyl; hydroxy- lower alkyl-oxy-lower alkyl; hydroxy-lower alkyl-amino; lower alkyl-amino-lower alkyl; amino; di-lower alkyl-amino; [N-(hydroxy-lower alkyl)-N-(lower alkyl)]- amino; aryl; aryl-amino; aryl-lower alkyl-amino; aryl-thio; aryl-lower alkyl-thio; aryloxy; aryl-lower alkyl-oxy; aryl-lower alky
• X represents oxygen; sulfur; NH; CH 2 or a bond;
• Y represents oxygen; sulfur or -NH-;
• Z represents oxygen; sulfur, -NH- or a bond
• Q represents -(CH 2 )R-; -(CH 2 ) m -C ⁇ C-(CH 2 ) p -, in case p represents 0 (zero), Z represents a bond; -CH 2 -cyclopropylen-CH 2 -;
• k represents the numbers 2, 3; 4, 5, or 6;
• n represents the numbers 1 , 2, or 3;
• p represents the numbers 0, 1 , 2 or 3;
• n the numbers 1 , 2, or 3;
• lower alkyl or lower alkoxy means straight and branched chain groups with one to seven carbon atoms, preferably 1 to 4 carbon atoms.
• Examples of lower alkyl and lower alkoxy groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert.-butyl, pentyl, hexyl, heptyl, methoxy, ethoxy, propoxy, n-butoxy, iso-butoxy, sec.-butoxy and tert.-butoxy.
• Lower alkylendioxy-groups are preferably methylene-dioxy, ethylene-dioxy, propylen- dioxy and butylen-dioxy groups.
• Examples of lower alkanoyl-groups are acetyl, propanoyl and butanoyl.
• Lower alkenylen means e.g.vinylen, propenylen and butenylen.
• Lower alkenyl and lower alkynyl means groups like ethylene, propylen, butylen, 2-methyl-propenyl, and ethinylen, propinylen, butinylen, pentinylen, 2-methyl-pentinyIen etc.
• Lower alkenyloxy means allyloxy, vinyloxy, propenyloxy and the like.
• the expression cycloalkyl means a saturated cyclic hydrocarbon ring with 3 to 7 carbon atoms , e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, which may be substituted with lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkoxy-lower alkyl and lower alkenylen groups.
• heterocyclyl means saturated or partially unsaturated four, five-, six- or seven-membered rings containing one or two nitrogen, oxygen or sulfur atoms which may be the same or different and which rings may be adequatly substituted with lower alkyl, amino, nitro, hydroxy, lower alkoxy, e.g.
• heteroaryl means six-membered aromatic rings containing one to four nitrogen atoms, benzofused six-membered aromatic rings containing one to three nitrogen atoms, five-membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, benzo- fused five-membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, five membered aromatic rings containig an oxygen and nitrogen atom and benzo fused derivatives thereof, five termed aromatic rings containing a sulfur and a nitrogen atom and benzo fused derivatives thereof, five- membered aromatic rings containing two nitrogen atoms and benzo fused derivatives thereof, five membered aromatic rings containing three nitrogen atoms and benzo fused derivatives thereof or the tetrazolyl ring; e.g.
• rings may be substituted with lower alkyl, lower alkenyl, amino, amino-lower alkyl, halogen, hydroxy, lower alkoxy, trifluoromethoxy, trifluoromethyl, carboxyl, carboxamidyl, thioamidyl, amidinyl, lower alkoxy, cyano, hydroxy-lower alkyl, lower alkoxy-lower alkyl or another heteroaryl- (preferrably tetrazolyl) or heterocyclyl-ring (preferrably 5-oxo-1,2,4-oxadiazolyl, 5-oxo-1 ,2,4- triazolyl, 5-oxo-1 ,2,4-thiadiazolyl, 5-thioxo-1 ,2,4-oxadiazolyl or 2-oxo-1 ,2,3,5- oxathiadiazolyl (e.g.
• aryl represents unsubstituted as well as mono-, di- or tri-substituted aromatic rings with 6 to 10 carbon atoms like phenyl or naphthyl rings which may be substituted with aryl, halogen, hydroxy, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkenyloxy, lower alkynyl-lower alkyl-oxy, lower alkenylen, lower alkylenoxy, lower alkylenoxy or lower alkylendioxy forming with the phenyl ring a five- or six-membered ring, hydroxy-lower alkyl, hydroxy-lower alkenyl, hydroxy-lower alkyl-lower alkynyl, lower alkoxy-lower alkyl, lower alkoxy-lower alkoxy, trifluoromethyl, trifluoromethoxy, cycloalkyl, hydroxy-cycloalkyl,
• Especially preferred compounds are compounds of general formula I wherein R 3 represents phenyl or mono-substituted phenyl substituted with lower alkoxy, especially methoxy and X represents oxygen.
• a second group of especially preferred compounds of general formula I are the compounds wherein R 3 represents phenyl or mono-substituted phenyl substituted with lower alkoxy, especially methoxy, and wherein X, Y and Z represent oxygen.
• a fifth group of especially preferred compounds of general formula I are the compounds wherein R 2 represents heteroaryl, R 3 represents phenyl or mono- substituted phenyl substituted with halogen, lower alkyl, lower alkenyl, methoxy, amino, lower alkyl-amino, lower alkyl-thio, hydroxy, hydroxymethyl and lower alkanoyl; X, Y and Z represent oxygen, Q represents -(CH 2 ) 2 -.
• R 1 , R 2 , R 3 , R 4 , Y, Q, Z, and n are as defined in general formula I above, and pharmaceutically acceptable salts of compounds of formula II. Also preferred are compounds of formula
• R 1 , R 2 , R 4 , Y, Q and Z and n are as defined in general formula I above, and pharmaceutically acceptable salts of compounds of formula III.
• R 1 , R 2 , R 4 , Q, and n are as defined in general formula I above, and pharmaceutically acceptable salts of compounds of formula IV.
• Another especially preferred group of compounds are compounds of formula V
• R and R 2 are as defined in general formula I above, and pharmaceutically acceptable salts thereof.
• Especially preferred compounds among the group of compounds of formula V are those wherein R 2 represents heteroaryl.
• salts encompasses either salts with inorganic acids or organic acids like hydrohalogenic acids, e.g. hydrochloric or hydrobromic acid; sulfuric acid, phosphoric acid, nitric acid, citric acid, formic acid, acetic acid, maleic acid, tartaric acid, methylsulfonic acid, p- toluolsulfonic acid and the like or in case the compound of formula I is acidic in nature with an inorganic base like an alkali or earth alkali base, e.g. sodium hydroxide, potassium hydroxide, calcium hydroxide etc.
• hydrohalogenic acids e.g. hydrochloric or hydrobromic acid
• an inorganic base like an alkali or earth alkali base, e.
• the compounds of the general formula I might have one or more asymmetric carbon atoms and may be prepared in form of optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and also in the meso-form.
• the present invention encompasses all these forms. Mixtures may be separated in a manner known per se, i.e. by column chromatography, thin layer chromatography, HPLC, crystallization etc.
• the described compounds of the general formula I and their pharmaceutically acceptable salts may be used for treatment of diseases which are associated with an increase in vasoconstriction, proliferation or inflammation due to endothelin.
• diseases which are associated with an increase in vasoconstriction, proliferation or inflammation due to endothelin.
• diseases are hypertension, coronary diseases, cardiac insufficiency, renal and myocardial ischemia, renal failure, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, Raynaud's syndrome, portal hypertension and pulmonary hypertension.
• Atherosclerosis prevention of restenosis after balloon or stent angioplasty, inflammation, stomach and duodenal ulcer, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, as well as other diseases presently known to be related to endothelin.
• compositions may be administered in enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions, in nasal form like sprays or rectically in form of suppositories.
• enteral or oral form e.g. as tablets, dragees, gelatine capsules, emulsions, solutions or suspensions
• nasal form like sprays or rectically in form of suppositories.
• These compounds may also be administered in intramuscular, parenteral or intravenous form, e.g. in form of injectable solutions.
• compositions may contain the compounds of formula I as well as their pharmaceutically acceptable salts in combination with inorganic and/or organic excipients which are usual in the pharmaceutical industry like lactose, maize or derivatives thereof, talcum, stearinic acid or salts of these materials.
• vegetable oils, waxes, fats, liquid or half-liquid polyols etc. may be used.
• solutions and sirups e.g. water, polyols, saccharose, glucose etc. are used.
• injectables are prepared by using e.g. water, polyols, alcohols, glycerin, vegetable oils, lecithin, liposomes etc.
• Suppositories are prepared by using natural or hydrogenated oils, waxes, fatty acids (fats ), liquid or half-liquid polyols etc.
• compositions may contain in addition preservatives, stabilisation improving substances, viscosity improving or regulating substances, solubility improving substances, sweeteners, dyes, taste improving compounds, salts to change the osmotic pressure, buffer, anti-oxidants etc.
• the compounds of formula I may also be used in combination with one or more other therapeutically useful substances e.g. ⁇ - and ⁇ -blockers like phentolamine, phenoxybenzamine, atenolol, propranolol, timolol, metoprolol, carteolol etc.; Vasodilators like hydralazine, minoxidil, diazoxide, flosequinan etc.; Calcium- antagonists like diltiazem, nicardipine, nimodipine, verapamil, nifedipine etc.; ACE-inhibitors like cilazapril, captopril, enalapril, lisinopril etc.; Potassium activators like pinacidil etc.; Angiotensin II antagonists; Diuretics like hydrochlorothiazide, chlorothiazide, acetolamide, bumetanide, furosemide, metolazone
• the dosage may vary within wide limits but should be adapted to the specific situation.
• the dosage given daily in oral form should be between about 3 mg and about 3 g, preferably between about 10 mg and about 1 g, especially preferred between 5 mg and 300 mg, per adult with a body weight of about 70 kg.
• the dosage should be administered preferably in 1 to 3 doses per day which are of equal weight.
• children should receive lower doses which are adapted to body weight and age.
• Compounds of the general formula I of the present invention can be prepared according to the general sequence of reactions outlined below. For simplicity and clarity reasons sometimes only parts of the synthetic possibilities which lead to compounds of general formula I are described. The literature references given in brackets [ ] are set forth at the end of this paragraph.
• the desired compounds of general formula I can be prepared by reacting a compound of the formula 1 :
• G 1 is a reactive residue, preferentially a chlorine atom, and the other symbols are as defined in general formula I above, with a compound of the formula 2:
• the compounds of general formula I may also be prepared by reacting a compound of formula 3:
• G 2 is a reactive residue, such as a halogen atom, and R 2 is as defined in general formula I above.
• the compounds of general formula I may also be prepared by reacting a compound of the formula 5:
• G 3 is a lower alkylsulfonyl group or a phenylsulfonyl group or a halogen atom, and the other symbols are the same as described in general formula I above, or a salt thereof, with a compound of the formula 6:
• R is as defined in general formula I above, or a salt thereof.
• Analog of Formula 3 a) NaOMe, MeOH then NH 4 CI or LiN(Si(CH 3 ) 3 ) 2 then HCI/i-PrOH; b) K 2 CO 3 , acetone; c) NaOMe, MeOH; d) POCI 3 ; e) NH 3 /THF then KOtBu, MeOH; f) DMSO; g) NaH, THF, DMF;
• the amidines 8 were synthesized applying standard methodology [1] by reaction of the appropriate nitrile 7 either with sodium methylate in methanol followed by addition of ammonium chloride or by reaction with lithium hexamethyldisilazane followed by addidion of hydrochloric acid in /-propanol.
• the 2-substituted malonic esters 10 were prepared according to published procedures [2] by reacting dimethylchloromalonate (9) with the appropriate alcohol 11 in acetone and potassium carbonate as base. The compounds 10 were dissolved in methanol and sodium methylate was added and stirring was continued for about 30 min followed by the addition of an amidine derivative 8. Stirring at ambient temperature was continued for another 8 h. After acidic work up the 4,6- dihydroxypyrimidines 12 could be isolated in yields of 70 to 90% [2].
• the pyrimidine derivatives 16 are the key intermediates which can be transformed to the desired final products of general formula I either by applying procedures outlined under Possibility A or they can be transformed to the derivatives 18 by reaction with a di-hydroxy-compound represented by formula 17 in the presence of a base such as sodium hydride in a solvent like THF at rt to 90°C and can then be transformed to final compounds according to the general formula I by applying procedures outlined under Possibility B above.
• the product was further purified by crystallisation from methanol :diethyl ethe ⁇ pentane to give 2-pyridin-2- yl-ethanesulfonic acid [6-(2-hydroxy-ethoxy)-5-(2-methoxy-phenoxy)-2-pyridin-4- yl-pyrimidin-4-yl]-amide (280 mg) as beige crystals.
• Phenyl-methanesulfonamide potassium salt was prepared in analogy to the procedures given in Referential Example 1d and 1e using commercial phenyl- methanesulfonyl chloride.
• p-Tolyl-methanesulfonyl chloride was prepared by oxidising commercially available p-tolyl-methanethiol with N-chlorosuccinimide in analogy to the procedure disclosed in [9].
• N-[6-(3-Hydroxy-propoxy)-5-(2-methoxy-phenoxy)-[2,2']bipyrimidinyl-4-yl]-C- phenyl-methanesulfonamide was prepared in analogy to the procedures given in Referential Example 20 using propane-1 ,3-diol instead of ethylene glycol.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Pain & Pain Management (AREA)
• Pulmonology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Rheumatology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (2)

Family

ID=8164105

Family Applications (1)

Country Status (18)

Cited By (12)

Families Citing this family (2)

Citations (3)

Family Cites Families (8)

• 2001
  • 2001-08-28 NZ NZ524172A patent/NZ524172A/en unknown
  • 2001-08-28 WO PCT/EP2001/009894 patent/WO2002024665A1/en not_active Ceased
  • 2001-08-28 US US10/381,568 patent/US7091201B2/en not_active Expired - Fee Related
  • 2001-08-28 HU HU0303364A patent/HUP0303364A3/hu unknown
  • 2001-08-28 BR BR0114082-5A patent/BR0114082A/pt not_active Application Discontinuation
  • 2001-08-28 ES ES01980288T patent/ES2333409T3/es not_active Expired - Lifetime
  • 2001-08-28 MX MXPA03001991A patent/MXPA03001991A/es active IP Right Grant
  • 2001-08-28 KR KR1020037003599A patent/KR100835770B1/ko not_active Expired - Fee Related
  • 2001-08-28 DE DE60140263T patent/DE60140263D1/de not_active Expired - Lifetime
  • 2001-08-28 AU AU2002212171A patent/AU2002212171B2/en not_active Ceased
  • 2001-08-28 IL IL15436401A patent/IL154364A0/xx unknown
  • 2001-08-28 CA CA2423351A patent/CA2423351C/en not_active Expired - Fee Related
  • 2001-08-28 JP JP2002529075A patent/JP2004509874A/ja not_active Ceased
  • 2001-08-28 CN CNB01815896XA patent/CN1326841C/zh not_active Expired - Fee Related
  • 2001-08-28 AU AU1217102A patent/AU1217102A/xx active Pending
  • 2001-08-28 AT AT01980288T patent/ATE446289T1/de active
  • 2001-09-24 AR ARP010104490A patent/AR032896A1/es not_active Application Discontinuation
• 2003
  • 2003-03-24 ZA ZA200302292A patent/ZA200302292B/en unknown
  • 2003-03-24 NO NO20031332A patent/NO20031332L/no not_active Application Discontinuation

Patent Citations (3)

Also Published As

Similar Documents

Legal Events